Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders

Rakez Kayed, George R. Jackson

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Alzheimer disease (AD) is the most common neurodegenerative disorder. Currently available therapies may slow cognitive decline but do not alter underlying disease processes. Considerable effort over the last decade has been directed toward the development of vaccines for AD; these have been primarily directed against the Aβ peptide, a component of senile plaques. More recently, alternative approaches have begun to target the microtubule binding protein tau, a component of neurofibrillary tangles. Immunotherapies based upon oligomeric species of tau represent a promising new approach for AD.

Original languageEnglish (US)
Pages (from-to)359-363
Number of pages5
JournalCurrent Opinion in Immunology
Volume21
Issue number3
DOIs
StatePublished - Jun 2009

Fingerprint

Immunotherapy
Alzheimer Disease
Microtubule Proteins
Neurofibrillary Tangles
Amyloid Plaques
Neurodegenerative Diseases
Carrier Proteins
Vaccines
Peptides
Therapeutics
Cognitive Dysfunction

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. / Kayed, Rakez; Jackson, George R.

In: Current Opinion in Immunology, Vol. 21, No. 3, 06.2009, p. 359-363.

Research output: Contribution to journalArticle

@article{e5fd2ff246904cefa6571fe73265725b,
title = "Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders",
abstract = "Alzheimer disease (AD) is the most common neurodegenerative disorder. Currently available therapies may slow cognitive decline but do not alter underlying disease processes. Considerable effort over the last decade has been directed toward the development of vaccines for AD; these have been primarily directed against the Aβ peptide, a component of senile plaques. More recently, alternative approaches have begun to target the microtubule binding protein tau, a component of neurofibrillary tangles. Immunotherapies based upon oligomeric species of tau represent a promising new approach for AD.",
author = "Rakez Kayed and Jackson, {George R.}",
year = "2009",
month = "6",
doi = "10.1016/j.coi.2009.05.001",
language = "English (US)",
volume = "21",
pages = "359--363",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders

AU - Kayed, Rakez

AU - Jackson, George R.

PY - 2009/6

Y1 - 2009/6

N2 - Alzheimer disease (AD) is the most common neurodegenerative disorder. Currently available therapies may slow cognitive decline but do not alter underlying disease processes. Considerable effort over the last decade has been directed toward the development of vaccines for AD; these have been primarily directed against the Aβ peptide, a component of senile plaques. More recently, alternative approaches have begun to target the microtubule binding protein tau, a component of neurofibrillary tangles. Immunotherapies based upon oligomeric species of tau represent a promising new approach for AD.

AB - Alzheimer disease (AD) is the most common neurodegenerative disorder. Currently available therapies may slow cognitive decline but do not alter underlying disease processes. Considerable effort over the last decade has been directed toward the development of vaccines for AD; these have been primarily directed against the Aβ peptide, a component of senile plaques. More recently, alternative approaches have begun to target the microtubule binding protein tau, a component of neurofibrillary tangles. Immunotherapies based upon oligomeric species of tau represent a promising new approach for AD.

UR - http://www.scopus.com/inward/record.url?scp=67049136162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67049136162&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2009.05.001

DO - 10.1016/j.coi.2009.05.001

M3 - Article

C2 - 19482462

AN - SCOPUS:67049136162

VL - 21

SP - 359

EP - 363

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

IS - 3

ER -